/
CELC
$100.58+$0.52 (+0.53%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$4.9B
49M shares
52-week range
$12.48 – $151.02
64% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Borrow rate
0.49%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$76.47
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $223.0K | $0 | $0 | $0 | $0 | $0 | $0 | $167.0K |
| Gross profit | −$223.0K | $0 | $0 | $0 | $0 | $0 | $0 | −$167.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $6.3M | $6.3M | $7.7M | $25.8M | $35.3M | $60.6M | $104.2M | $145.0M |
| Operating income | −$7.9M | −$7.8M | −$9.6M | −$28.4M | −$39.4M | −$66.2M | −$113.3M | −$172.2M |
| EBITDA | −$7.7M | −$7.5M | −$9.2M | −$28.0M | −$38.1M | −$58.3M | −$101.4M | −$159.7M |
| Net income | −$7.5M | −$7.4M | −$9.5M | −$29.6M | −$40.4M | −$63.8M | −$111.8M | −$177.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.74 | -0.69 | -0.89 | -2.28 | -2.68 | -2.69 | -2.83 | -3.78 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $53M | $-4.03 | $-4.26–$-3.90 | 5 |
| 2027 | $383M | $-0.48 | $-8.71–$5.43 | 5 |
| 2028 | $732M | $3.39 | $0.27–$6.66 | 6 |
| 2029 | $1.2B | $7.74 | $2.81–$13.55 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Celcuity Inc. Common Stock
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
www.celcuity.com- Employees
- 155
- IPO / List date
- Sep 20, 2017
- HQ
- MINNEAPOLIS, MN
Held by traders on TradeandTell
No one on the platform currently holds CELC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 194,800 | $9.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CELC yet.
